ACADIA Pharmaceuticals Inc (ACAD) stock forecast · P/E 15, rev $576.0M
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
This ACAD forecast page states what the cached financials imply — not a price target and not a guarantee. ACADIA Pharmaceuticals Inc outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported ACAD revenue for 2026-06-30 was $576.0M. Net income was $35.1M. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Period-over-period revenue change is not in cache for ACAD, so this page does not invent a growth rate.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next ACAD 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the ACAD stock page.
Not investment advice.